{"id":"propranolol-and-etodolac","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Gastrointestinal upset"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Propranolol blocks beta-adrenergic receptors, decreasing cardiac output and sympathetic nervous system activity. Etodolac inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain. The combination may be investigated for conditions where both cardiovascular modulation and anti-inflammatory effects are therapeutically beneficial.","oneSentence":"This combination uses propranolol (a beta-blocker) to reduce heart rate and blood pressure, and etodolac (an NSAID) to reduce inflammation and pain.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:30:34.198Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Phase 3 investigational indication (specific indication not publicly disclosed)"}]},"trialDetails":[{"nctId":"NCT06839144","phase":"PHASE2","title":"Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression","status":"RECRUITING","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2025-03-12","conditions":"Ovarian Cancer, Ovarian Cancer Metastatic Recurrent","enrollment":60},{"nctId":"NCT05429970","phase":"NA","title":"A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-06-17","conditions":"Ovarian Cancer, Ovarian Carcinoma, Stage II Ovary Cancer","enrollment":35},{"nctId":"NCT03838029","phase":"PHASE2","title":"Perioperative Intervention to Reduce Metastatic Processes in Pancreatic Cancer Patients Undergoing Curative Surgery","status":"UNKNOWN","sponsor":"Assaf-Harofeh Medical Center","startDate":"2019-11-20","conditions":"Pancreatic Neoplasms","enrollment":210},{"nctId":"NCT03919461","phase":"PHASE2","title":"Colorectal Metastasis Prevention International Trial 2","status":"RECRUITING","sponsor":"Assaf-Harofeh Medical Center","startDate":"2019-02-28","conditions":"Colorectal Neoplasms","enrollment":200},{"nctId":"NCT01857817","phase":"PHASE2","title":"Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer","status":"TERMINATED","sponsor":"Vicus Therapeutics","startDate":"2013-06","conditions":"Prostatic Neoplasms","enrollment":35},{"nctId":"NCT01265576","phase":"PHASE2","title":"Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)","status":"UNKNOWN","sponsor":"Vicus Therapeutics","startDate":"2010-12","conditions":"HCC","enrollment":20},{"nctId":"NCT00502684","phase":"NA","title":"Perioperative Administration of COX 2 Inhibitors and Beta Blockers to Women Undergoing Breast Cancer Surgery","status":"UNKNOWN","sponsor":"Kaplan Medical Center","startDate":"2014-06","conditions":"Primary Operable Breast Cancer","enrollment":32},{"nctId":"NCT00888797","phase":"PHASE3","title":"β-adrenergic Blocker and a COX2 Inhibitor for Prevention of Colorectal Cancer Recurrence","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2010-01","conditions":"Colorectal Neoplasms","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":22,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Deralin and etopan"],"phase":"phase_3","status":"active","brandName":"Propranolol and etodolac","genericName":"Propranolol and etodolac","companyName":"Assaf-Harofeh Medical Center","companyId":"assaf-harofeh-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses propranolol (a beta-blocker) to reduce heart rate and blood pressure, and etodolac (an NSAID) to reduce inflammation and pain. Used for Phase 3 investigational indication (specific indication not publicly disclosed).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}